We demonstrate that the CaSR suppresses EMT and the stem cell-like phenotype both, in vivo in the colon of mice and in vitro, in colon cancer cells, providing rationale for developing pharmacological agents to modulate CaSR sensitivity in colorectal cancer to prevent tumor progression. This evidence concerns the gene CASR and colonic neoplasm.